Return
Company Page
Phagos
Founders
Phagos develops AI-powered bacteriophage therapies as a sustainable alternative to antibiotics to combat antimicrobial resistance. The company combines microbiology and artificial intelligence to create personalized, ultra-targeted phage-based treatments for bacterial diseases. Its patented platform can develop customized treatments in 2 months, initially focusing on animal health (treating Salmonella and E. coli in livestock) with plans to extend to human health. Phagos became the first company worldwide authorized to market personalized phage-based veterinary drugs, achieving a groundbreaking regulatory milestone in the EU.
Company Founded in 2021
Healthtech & Biotech